Viropharma (VPHM +4.3%) gets a lift today from a valuation upgrade to Overweight at JPMorgan...

|By:, SA News Editor

Viropharma (VPHM +4.3%) gets a lift today from a valuation upgrade to Overweight at JPMorgan with a price target of $32 a share. Analyst Brian Abrahams thinks the competitive threats to VPHM's Angioedema treatment Cinryze have been overstated relative to its peers, noting that although some early-stage treatments by its competitors are "worth keeping an eye on," they have characteristics which make them a less-attractive alternative.